Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 0.70 |
| ▸ | FBP1 | P09467 | 2/20 | 0.59 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.58 |
| ▸ | AURKA | O14965 | 1/20 | 0.58 |
| ▸ | INSR | P06213 | 1/20 | 0.58 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.58 |
| ▸ | FLT4 | P35916 | 1/20 | 0.58 |
| ▸ | KDR | P35968 | 1/20 | 0.58 |
| ▸ | CLK1 | P49759 | 1/20 | 0.58 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.58 |
| ▸ | TEK | Q02763 | 1/20 | 0.58 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.57 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.57 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.57 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3575576 | 0.95 | EGFR (0.64) | EGFRFBP1ERBB2AURKAINSR | |
| SCHEMBL6674011 | 0.95 | EGFR (0.64) | EGFRFBP1ERBB2AURKAINSR | |
| SCHEMBL6995758 | 0.95 | EGFR (0.63) | EGFRERBB2KDRHDAC3HDAC4 | |
| SCHEMBL26082 | 0.94 | EGFR (0.61) | EGFRFBP1ERBB2AURKAINSR | |
| SCHEMBL4576907 | 0.92 | FBP1 (0.60) | EGFRFBP1ERBB2AURKAINSR | |
| SCHEMBL15928079 | 0.92 | FBP1 (0.60) | EGFRFBP1ERBB2AURKAINSR | |
| SCHEMBL19293607 | 0.92 | FBP1 (0.66) | EGFRFBP1ERBB2AURKAINSR | |
| SCHEMBL15928220 | 0.92 | EGFR (0.61) | EGFRFBP1ERBB2AURKAINSR | |
| SCHEMBL642350 | 0.90 | EGFR (0.64) | EGFRFBP1ERBB2AURKAINSR | |
| SCHEMBL17538495 | 0.89 | EGFR (0.63) | EGFRFBP1ERBB2AURKAINSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1322645-A2 | QUINAZOLINES, MEDICAMENTS, WHICH CONTAIN THESE COMPOUNDS AND WHICH ARE EFFECTIVE AS TYROSINE KINASE INHIBITORS, THEIR USE, AND METHODS FOR THE PRODUCTION THEREOF | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-07-02 | — | — | EP | disclosed |
| EP-1315716-A1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE, AND METHODS FOR THE PRODUCTION THEREOF | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-06-04 | — | — | EP | disclosed |
| US-20020082270-A1 | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-06-27 | — | — | US | disclosed |
| US-6403580-B1 | HAVING AN INHIBITORY EFFECT ON SIGNAL TRANSDUCTION MEDIATED BY TYROSINE KINASES, THE USE THEREOF FOR TREATING DISEASES, PARTICULARLY TUMORAL DISEASES, DISEASES OF THE LUNGS AND RESPIRATORY TRACT, AND THE PREPARATION THEREOF. | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-06-11 | — | — | US | disclosed |
| WO-2002018375-A1 | QUINAZOLINES, MEDICAMENTS, WHICH CONTAIN THESE COMPOUNDS AND WHICH ARE EFFECTIVE AS TYROSINE KINASE INHIBITORS, THEIR USE, AND METHODS FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-03-07 | — | — | WO | disclosed |
| WO-2002018370-A1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE, AND METHODS FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082270-A1 | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases | MAP3K1, MAP3K19, MAP3K20 | EGFR 165/4885FBP1 2544/4885ERBB2 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.